News

January 13, 2017

Biogen Presents New ENDEAR Data Showing SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation

Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

January 12, 2017

Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza

Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza

With the news today that the first-ever patient has received the first commercial Spinraza dose, we are releasing an updated version of our SMA drug pipeline. This new version reflects the approval of Spinraza, as well as the true start of a key stage to ensure that more and more patients are...

READ MORE   |  

Topics: Community & Awareness, Advocacy, Front Page News

January 9, 2017

SMA Patient-Focused Drug Development Meeting with FDA Set for April 18, 2017

SMA Patient-Focused Drug Development Meeting with FDA Set for April 18, 2017

Tuesday, April 18, 2017, has been announced as the date for the SMA Patient-Focused Drug Development Meeting with the FDA.

At the Patient Focused Drug Development (PFDD) Meeting, individuals and families from throughout our community will have the opportunity to share their stories...

READ MORE   |  

Topics: Community & Awareness, Advocacy, Front Page News

Items 1 - 3 of 306  12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software